<DOC>
	<DOCNO>NCT00216593</DOCNO>
	<brief_summary>The purpose study assess effectiveness safety galantamine hydrobromide treatment patient severe Alzheimer 's disease .</brief_summary>
	<brief_title>Treatment Severe Alzheimer 's Disease : Evaluation Efficacy Safety Galantamine Hydrobromide Controlled Study</brief_title>
	<detailed_description>This multicenter , 1-year study include randomize , 6-month , double-blind , placebo-controlled phase 6-month open-label extension galantamine hydrobromide treatment subject severe Alzheimer 's disease . The open-label extension optional al patient . Patients eligible study randomize treatment either galantamine hydrobromide placebo 6 month first phase study . The principal measure include result Severe Impairment Battery Minimum Data Set-Activities Daily Living test , assess aspect cognition behavior , impact patient 's ability perform normal daily activity . Additional evaluation include Neuro-Psychiatric Inventory-Nursing Home Version measure 2 subscales Minimum Data Set test assess patient behavior , social physical functioning , level caregiver support need , impact patient 's caregiver ; Mini-Mental State Examination , assess cognitive ability ; external health-and social-service use . Safety tolerability evaluate basis adverse event report , physical examination , electrocardiogram , vital sign , laboratory parameter . The study hypothesis treatment galantamine , compare placebo , significantly improve cognition ability function patient severe Alzheimer 's disease , generally well-tolerated . Galantamine hydrobromide tablet take mouth two time daily : 4 week 8 milligram ( mg ) /day , 4 week 16 mg/day , increase 24 mg/day remainder 6 month . Dose may reduce investigator 's discretion . Galatamine hydrobromide additional 6 month open-label phase .</detailed_description>
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Dementia</mesh_term>
	<mesh_term>Galantamine</mesh_term>
	<criteria>Diagnosis Alzheimer 's type dementia , rat severe progressive worsen memory cognitive function brain imaging ( CTor MRI scan ) within last 3 year ability mobile ( aid unaided ) sufficient vision hear comply test . Dementia cause cerebrovascular disease disturbance consciousness , delirium , psychosis severe aphasia major sensorimotor impairment cognitive impairment due acute cerebral trauma , hypoxic cerebral damage , vitamin deficiency , infection , primary metastatic cerebral neoplasia , endocrine metabolic disease mental retardation , pregnant nursing woman without adequate contraception .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2010</verification_date>
	<keyword>dementia</keyword>
	<keyword>cognition function</keyword>
	<keyword>Alzheimer disease</keyword>
	<keyword>behavioral symptom</keyword>
	<keyword>galantamine hydrobromide</keyword>
</DOC>